Clinical trial
Cap/Iri Plus Cetuximab Compared to Cap/ox Plus Cetuximab in Patients With…
NCT00254137 · Ludwig-Maximilians - University of Munich, Other · Completed
Key facts
| NCT number | NCT00254137 |
|---|---|
| Title | Cap/Iri Plus Cetuximab Compared to Cap/ox Plus Cetuximab in Patients With Metastatic Colorectal Cancer. |
| Official title | A Randomized Phase II-study to Evaluate the Safety and Efficacy of Capecitabine Plus Irinotecan Plus Cetuximab Compared to Capecitabine Plus Oxaliplatin Plus Cetuximab in First-line Treatment of Patients With Metastatic Colorectal Cancer. |
| Lead sponsor | Ludwig-Maximilians - University of Munich, Other |
| Collaborators | Merck Sharp & Dohme LLC Industry Sanofi Pfizer Hoffmann-La Roche |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Colorectal Cancer |
| Intervention type | Drug |
| Interventions | capecitabine, irinotecan, oxaliplatin, cetuximab |
| Enrollment | 92 |
| Start date | Sep 1, 2004 |
| Completion | Nov 1, 2006 |
| First posted | Nov 15, 2005 |
| Last update posted | Oct 28, 2010 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: